BeiGene, Mirati: Preliminary Data from Ongoing Trial Demonstrated Antitumor Activity

By Michael Dabaie

BeiGene Ltd. (BGNE) and Mirati Therapeutics (MRTX) said preliminary data from an ongoing Phase 1b trial of tislelizumab in combination with sitravatinib in patients with platinum-resistant ovarian cancer demonstrated antitumor activity and was generally well tolerated.

"The initial results from this Phase 1b trial suggest further development of this combination for the treatment of advanced solid tumors, including platinum-resistant ovarian cancer, is warranted," Mirati Chief Executive Charles Baum said.

The Phase 1b trial of tislelizumab in combination with sitravatinib consists of nine disease-specific cohorts in patients with advanced solid tumors. The results were from cohort E in 20 patients with recurrent platinum-resistant ovarian cancer who didn't have prior exposure to anti-PD-1/PD-L1 agents. At the data cutoff, 17 patients were evaluable. Seven patients achieved a partial response, including four confirmed PRs. The overall response rate was 23.5% and eight patients achieved stable disease. The median duration of response wasn't reached.

The median progression-free response was 18 weeks and the PFS rate at 3 months and 6 months was 88.2% and 35.3% respectively.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

December 13, 2019 08:29 ET (13:29 GMT)

Mirati Therapeutics (NASDAQ:MRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024